Screener
Kyverna Therapeutics, Inc. KYTX Interest Income
Interest Income at other companies
Other financials
Where this comes from
Reported directly by Kyverna Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:InvestmentIncomeInterest.
The source filing: Kyverna Therapeutics, Inc.’s 10-Q, filed May 12, 2026.
- Filed
- May 12, 2026, 4:08 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-219397
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| General and administrative | 11,294 | 9,975 |
| Total operating expenses | 41,367 | 47,408 |
| Loss from operations | (41,367) | (47,408) |
| Interest income | 2,327 | 2,825 |
| Interest expense | (667) | (25) |
| Other expense, net | (21) | (27) |
| Total other income, net | 1,639 | 2,773 |
| Net loss | (39,728) | (44,635) |
Item 1. Financial Statements (unaudited)
FAQ
- What is Kyverna Therapeutics, Inc.'s interest income?
- Kyverna Therapeutics, Inc. (KYTX) reported interest income of $2.33M in Q1 2026.
- How has Kyverna Therapeutics, Inc.'s interest income changed year-over-year?
- Kyverna Therapeutics, Inc.'s interest income decreased by 17.6% year-over-year, from $2.83M to $2.33M.
- What is the long-term trend for Kyverna Therapeutics, Inc.'s interest income?
- Over 2 years (2023 to 2025), Kyverna Therapeutics, Inc.'s interest income has grown at a 99.6% compound annual growth rate (CAGR), from $2.28M to $9.09M.
- What does interest income mean?
- Income earned from interest-bearing assets including cash deposits, money market funds, treasury securities, corporate bonds, and customer financing receivables.
Ask your AI about Kyverna Therapeutics, Inc.'s interest income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude